Press release
Systemic Sclerosis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Systemic Sclerosis, historical and forecasted epidemiology as well as the Systemic Sclerosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.To Know in detail about the Systemic Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Sclerosis Market Forecast
https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Systemic Sclerosis Market Report:
• The Systemic Sclerosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The incidence and prevalence estimates of SSc in the United States were 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively, according to a study by Fan et al. (2020)
• According to Coi et al.'s analysis of the literature from 2021, the prevalence of SSc was found to be 22.2 per 100,000 people in Tuscany (Italy), with cases younger than 65 years old having the highest frequency (33.2 per 100,000, CI 95% 29.6-37.3)
• Key Systemic Sclerosis Companies: Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharmaceuticals, Certa Therapeutics, Castle Creek Biosciences, Mitsubishi Tanabe Pharma, Biocad, Prism Pharma Co., Ltd., Boehringer Ingelheim, Janssen Pharmaceutical K.K., GlaxoSmithKline, Bayer, Maruho Co., Ltd., Gesynta Pharma AB, Sanofi, and others
• Key Systemic Sclerosis Therapies: Brodalumab, MT-0551, EHP-101, KD025/Belumosudil, GS-248, Vasculan, FT011, FCX-013, MT-7117, Divozilimab, C-82, BI 685509, Guselkumab, GSK2330811, Riociguat (Adempas, BAY63-2521), nemolizumab, GS-248, SAR156597, and others
• The Systemic Sclerosis epidemiology based on gender analyzed that the female population is more prone to Systemic Sclerosis (SSc) as compared to the male population
• The Systemic Sclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Sclerosis pipeline products will significantly revolutionize the Systemic Sclerosis market dynamics.
Systemic Sclerosis Overview
A uncommon condition called systemic sclerosis (SSc) also known as Systemic Scleroderma may appear viscerally, particularly in the peripheral vascular, digestive, cardiac, and renal systems.
Get a Free sample for the Systemic Sclerosis Market Report
https://www.delveinsight.com/report-store/systemic-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Systemic Sclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Systemic Sclerosis Epidemiology Segmentation:
The Systemic Sclerosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Systemic Sclerosis
• Prevalent Cases of Systemic Sclerosis by severity
• Gender-specific Prevalence of Systemic Sclerosis
• Diagnosed Cases of Episodic and Chronic Systemic Sclerosis
Download the report to understand which factors are driving Systemic Sclerosis epidemiology trends @ Systemic Sclerosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Systemic Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis market or expected to get launched during the study period. The analysis covers Systemic Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Systemic Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Systemic Sclerosis Therapies and Key Companies
• Brodalumab: Kyowa Hakko Kirin
• MT-0551: Mitsubishi Tanabe Pharma Corporation
• EHP-101: Emerald Health Pharmaceuticals
• KD025/Belumosudil: Kadmon Corporation
• GS-248: Gesynta Pharma
• Vasculan: Cumberland Pharmaceuticals
• FT011: Certa Therapeutics
• FCX-013: Castle Creek Biosciences
• MT-7117: Mitsubishi Tanabe Pharma
• Divozilimab: Biocad
• C-82: Prism Pharma Co., Ltd.
• BI 685509: Boehringer Ingelheim
• Guselkumab: Janssen Pharmaceutical K.K.
• GSK2330811: GlaxoSmithKline
• Riociguat (Adempas, BAY63-2521): Bayer
• nemolizumab: Maruho Co., Ltd.
• GS-248: Gesynta Pharma AB
• SAR156597: Sanofi
Discover more about therapies set to grab major Systemic Sclerosis market share @ Systemic Sclerosis Treatment Market
https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Systemic Sclerosis Market Strengths
• Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Fabry disease.
• Newborn screening for Fabry disease has been implemented in several countries, enabling the early detection of individuals with Fabry mutations.
• Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy, and substrate reduction therapy.
Systemic Sclerosis Market Opportunities
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers
Scope of the Systemic Sclerosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Systemic Sclerosis Companies: Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharmaceuticals, Certa Therapeutics, Castle Creek Biosciences, Mitsubishi Tanabe Pharma, Biocad, Prism Pharma Co., Ltd., Boehringer Ingelheim, Janssen Pharmaceutical K.K., GlaxoSmithKline, Bayer, Maruho Co., Ltd., Gesynta Pharma AB, Sanofi, and others
• Key Systemic Sclerosis Therapies: Brodalumab, MT-0551, EHP-101, KD025/Belumosudil, GS-248, Vasculan, FT011, FCX-013, MT-7117, Divozilimab, C-82, BI 685509, Guselkumab, GSK2330811, Riociguat (Adempas, BAY63-2521), nemolizumab, GS-248, SAR156597, and others
• Systemic Sclerosis Therapeutic Assessment: Systemic Sclerosis current marketed and Systemic Sclerosis emerging therapies
• Systemic Sclerosis Market Dynamics: Systemic Sclerosis market drivers and Systemic Sclerosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Systemic Sclerosis Unmet Needs, KOL's views, Analyst's views, Systemic Sclerosis Market Access and Reimbursement
To know more about Systemic Sclerosis companies working in the treatment market, visit @ Systemic Sclerosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Systemic Sclerosis Market Report Introduction
2. Executive Summary for Systemic Sclerosis
3. SWOT analysis of Systemic Sclerosis
4. Systemic Sclerosis Patient Share (%) Overview at a Glance
5. Systemic Sclerosis Market Overview at a Glance
6. Systemic Sclerosis Disease Background and Overview
7. Systemic Sclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Systemic Sclerosis
9. Systemic Sclerosis Current Treatment and Medical Practices
10. Systemic Sclerosis Unmet Needs
11. Systemic Sclerosis Emerging Therapies
12. Systemic Sclerosis Market Outlook
13. Country-Wise Systemic Sclerosis Market Analysis (2019-2032)
14. Systemic Sclerosis Market Access and Reimbursement of Therapies
15. Systemic Sclerosis Market Drivers
16. Systemic Sclerosis Market Barriers
17. Systemic Sclerosis Appendix
18. Systemic Sclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Systemic Sclerosis Pipeline https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Systemic Sclerosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Systemic Sclerosis market. A detailed picture of the Systemic Sclerosis pipeline landscape is provided, which includes the disease overview and Systemic Sclerosis treatment guidelines.
Systemic Sclerosis Epidemiology https://www.delveinsight.com/report-store/systemic-sclerosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Systemic Sclerosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Systemic Sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products
Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Sclerosis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma here
News-ID: 3134208 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Systemic
Transformative Trends Impacting the Systemic Aspergillosis And Systemic Candidia …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Systemic Aspergillosis And Systemic Candidiasis Market Size By 2025?
The growth trend of the systemic aspergillosis and systemic candidiasis market has been steadily ascending in the past few years. The market size will inflate from $7.24 billion in 2024 to $7.59 billion in 2025, indicating…
Systemic Aspergillosis And Systemic Candidasis Market Size by Type, Application, …
According to Market Research Intellect, the global Systemic Aspergillosis And Systemic Candidasis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The growing prevalence of invasive fungal infections, especially in immunocompromised persons, is propelling the global…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market - Industry Over …
The systemic aspergillosis and systemic candidiasis treatment market is gaining significant attention within the global healthcare and pharmaceutical industries due to the increasing incidence of life-threatening fungal infections among immunocompromised individuals. Both systemic aspergillosis and systemic candidiasis are opportunistic fungal infections, often affecting patients with weakened immune systems due to cancer therapy, organ transplantation, HIV/AIDS, or intensive care treatments.
The systemic aspergillosis and systemic candidiasis treatment market was valued at approximately…
Europe Systemic Aspergillosis and Systemic Candidasis Market Comprehensive Analy …
The Europe systemic aspergillosis and systemic candidasis market is expected to reach US$ 2,237.55 million by 2027 was Valued at US$ 1,702.60 million in 2019; it is estimated to grow with a CAGR of 3.5% from 2020 to 2027.
The "Europe Systemic Aspergillosis and Systemic Candidasis Market" forecast 2027 report analyses the present and future competitive scenario of the analytics industry. Europe Systemic Aspergillosis and Systemic Candidasis Market report offers an…
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end…
